(Q37790624)

English

Comparative efficacy and overall safety of different doses of consensus interferon for treatment of chronic HCV infection: a systematic review and meta-analysis.

scientific article published on 21 September 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857094%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

0 references

Comparative efficacy and overall safety of different doses of consensus interferon for treatment of chronic HCV infection: a systematic review and meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857094%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Seyed Moayed Alavian

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857094%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Bita Behnava

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857094%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Seyed Vahid Tabatabaei

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857094%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

publication date

21 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857094%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

European Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857094%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

66

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857094%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857094%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1071-1079

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857094%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

https://scigraph.springernature.com/pub.10.1007/s00228-010-0881-7

0 references

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0881-7

21 January 2018

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0881-7

21 January 2018

Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0881-7

21 January 2018

Randomized controlled trial of consensus interferon with or without zinc for chronic hepatitis C patients with genotype 2.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0881-7

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of chronic hepatitis C by interferon for longer duration than six months

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Racial differences in response rates to consensus interferon in HCV infected patients naive to previous therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The safety and tolerability of daily infergen plus ribavirin in the treatment of naíïve chronic hepatitis C patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bias in clinical intervention research.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development and validation of MIX: comprehensive free software for meta-analysis of causal research data

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measuring inconsistency in meta-analyses

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of consensus interferon in the treatment of chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized controlled trial of consensus interferon with or without lactoferrin for chronic hepatitis C patients with genotype 1b and high viral load

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural history of chronic hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The global burden of hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, double-blind, controlled trial of consensus interferon in the treatment of Chinese patients with chronic hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Consensus interferon versus interferon-alpha 2b plus ribavirin in patients with relapsing HCV infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. The Consensus Interferon Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genotype does not affect pattern of HCV RNA decrease among responders during interferon treatment of chronic hepatitis C. Consensus Interferon Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Publication bias in clinical trials due to statistical significance or direction of trial results

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multicenter, randomized, controlled clinical trial of interferon alfacon-1 in comparison with lymphoblastoid interferon-alpha in patients with high-titer chronic hepatitis C virus infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. Consensus Interferon Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of chronic hepatitis C treatment failures: role of consensus interferon.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Consensus Interferon Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The treatment of chronic viral hepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Utility of hepatitis C virus serotypes in predicting response to treatment of chronic hepatitis C. Consensus Interferon Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20857094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00228-010-0881-7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857094%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857094%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37790624&oldid=2092688589"